The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...

Federal regulators shook up a rapidly growing pharmaceutical marketplace when they announced that tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, was no longer in shortage ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

Like many health plans, Lilla’s insurance didn’t cover Wegovy for weight loss use. Out of pocket, a month’s supply came with a price tag of more than $1,300. Even after applying a coupon from the drug ...

This lengthy study with the drug Mounjaro seems to point to even better success than they’d hoped. Eli Lilly, the mind behind ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And ...

The order would prevent the FDA from enforcing restrictions on compounding against larger facilities that have made copies of Lilly’s Mounjaro and Zepbound for telehealth ... tread lightly on ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Teva Pharmaceutical Industries will pay $450 to settle the Department of Justice's investigation into allegations of price fixing and misuse of funds for kickbacks. Other pharmaceutical news reports ...